Navigation Links
DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
Date:6/3/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2013 in Chicago.

DelMar presented additional clinical data from the company's ongoing Phase I/II clinical trial with VAL-083.  The trial is a dose-escalation study designed to assess the safety and activity of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma or secondary-progressive brain tumor who have failed standard therapies and have no viable treatment options. Three cohorts of patients have been enrolled so far, testing VAL-083 at 1.5mg/m2; 3.0mg/m2 and 5.0mg/m2.  A link to the company's poster can be found at: http://www.delmarpharma.com/DelMarASCO2013-11x17.pdf

Jeffrey Bacha , president & CEO of DelMar Pharmaceuticals, noted, "These new data presented at ASCO continue to demonstrate promise for VAL-083 as a potential treatment for cancer patients suffering from GBM as well as patients who are suffering from other cancers that have spread to the brain. Tumors of the brain are among the most challenging malignancies to treat. Median survival for patients with recurrent disease is approximately 6 months for glioblastoma multiforme.  Central nervous system metastases have evolved as a major contributor to cancer mortality because many new systemic therapies cannot reach tumors spreading to the brain."

Highlights of the DelMar ASCO
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
2. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
5. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
6. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
7. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
8. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
9. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
10. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
11. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 ... of drugs within human and veterinary oncology, has filed ... and Exchange Commission, in connection with the proposed public ... Stock Market. The number of American Depositary Shares, representing ... for the offering have not yet been determined. An ...
(Date:7/7/2015)...  Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing ... and CEO, Chandler D. Robinson MD, MBA, ... Award. The British Council selected one recipient from each ... , and the United States ... who have leveraged their U.K. education in their subsequent ...
(Date:7/7/2015)...   Abide Therapeutics , a developer of ... dosing of the first subject in a Phase ... endocannabinoid system modulator. ABX-1431 was discovered with Abide,s ... drug candidates that target serine hydrolases, a large ... human physiology and disease. "This is ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
... 2011 Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, announced today ... of an additional $50 million of the company,s shares ... authorization, the total amount available for share repurchases by ...
... University of California San Diego Extension Certificate Program in ... seminar from 5 to 7 pm Thursday, December 8 ... The seminar on conducting clinical trials in Latin America, ... but advance registration is required. The certificate ...
Cached Medicine Technology:Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 2Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 3UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 2UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 3
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... a leading provider of unified communication management solutions, has announced the release ... Select. , This service pack includes a number of enhancements to the ...
(Date:7/7/2015)... ... 2015 , ... On May 29, 2015, Health Canada announced that they had ... claims for gluten free oats and foods that contain them as ingredients. , “We ... (GFCP) to include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory ...
(Date:7/7/2015)... ... ... is holding an onsite job fair to hire 400 people for its new site in ... Wednesday, July 8, and Thursday, July 9, from 9:00 a.m. – 5:00 p.m. , During ... as holding onsite interviews. Interested parties are encouraged to attend the job fair or ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... they have been selected by the Department of Vermont Health Access to provide ... Management Information System (MMIS) and Integrated Contact Center System project. , Vermont is ...
(Date:7/6/2015)... Los Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... resource for finding medical providers for personal injury victims. Throughout the company’s history ... that collectively deliver the care victims need in their recovery. And while Doctors ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... CHICAGO June 6, 2011 An analysis linking ... nearly 232,000 adult cancer cases in western Washington during ... survival: Insolvency rates increase along with the length of ... financial stress due to income loss and out-of-pocket costs ...
... proteins in frog skins which could be used to ... the growth of blood vessels. The award-winning research, led ... has identified two proteins, or ,peptides, which can be ... ,angiogenesis, the process by which blood vessels grow ...
... 7, 2011 The discovery of a potential new ... team has been awarded Project of the Year by ... which began in 2002 under the direction of Dr. ... enzyme that the malaria parasite requires for survival. The ...
... MONDAY, June 6 (HealthDay News) -- Though it,s not clear ... a new study says that men who bully others during ... wives and girlfriends. "It helps people think of bullying ... G. Silverman, an associate professor at the Harvard School of ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
... News) -- Many people who suffer from obstructive sleep apnea ... weight, a new study suggests. Without realizing it, ... night as they struggle to breathe. The condition can cause ... are treated with continuous positive airway pressure (CPAP), a treatment ...
Cached Medicine News:Health News:Study finds bankruptcy rates among cancer patients increase along with survival time 2Health News:Scientists unlock potential of frog skin to treat cancer 2Health News:UT Southwestern research team's anti-malarial work wins international Project of the Year award 2Health News:Boys Who Bully May Grow Up to Be Abusive Men 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2Health News:Weight Loss May Help Sleep Apnea Symptoms 2
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Four way compression with simple contact closure...
Medicine Products: